Physician

Shobha Rani Nalluri, MD

According to 2025 Medicare claims, Shobha Nalluri, MD (NPI: 1578759387) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Prince George, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23805-0002.

Nalluri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 580 traditional Medicare patients, billed 88,155 HCPCS/CPT codes, and received $1,976,023 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,505 prescription claims across 206 beneficiaries totaling $2,693,084 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 70 claims. Open Payments data shows 90 records totaling $2,019. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $572,766 to $2,693,084. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	534	75,861	$1,114,137
2016	665	105,128	$1,560,510
2017	793	144,012	$2,035,042
2018	788	168,694	$1,865,951
2019	755	130,902	$1,613,638
2020	787	104,609	$1,578,943
2021	693	104,431	$1,364,222
2022	649	111,422	$1,768,877
2023	609	103,862	$1,597,898
2024	580	88,155	$1,976,023

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	122	956	$572,766
2016	131	917	$517,313
2017	124	1,071	$761,407
2018	132	1,001	$982,018
2019	170	1,267	$1,813,304
2020	180	1,246	$2,039,002
2021	158	1,119	$2,076,016
2022	177	1,189	$2,211,908
2023	194	1,381	$2,322,054
2024	206	1,505	$2,693,084

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	41	$25,928
2016	N/R	N/R	N/R
2017	N/R	61	$13,275
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$1,967
2021	N/R	14	$1,619
2022	N/R	36	$1,653
2023	N/R	70	$16,291
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	83	315	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	197	536	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	252	440	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	178	224	$12
96372	Injection of drug or substance under skin or into muscle	93	242	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	1,204	$799,710
Cabometyx	Cabozantinib S-Malate	24	720	$583,946
Lenalidomide	Lenalidomide	30	840	$398,240
Ibrance	Palbociclib	17	476	$263,068
Lynparza	Olaparib	12	360	$198,684

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	90	$2,019	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shobha Rani Nalluri, MD?

Tedicare shows public-source Medicare data for Shobha Rani Nalluri, MD (NPI 1578759387), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shobha Rani Nalluri, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shobha Rani Nalluri, MD?

Shobha Rani Nalluri, MD is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Shobha Rani Nalluri, MD have Open Payments data?

Shobha Rani Nalluri, MD has 90 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.